Neurobiology of suicidal behaviour

Nature Reviews Neuroscience

Volumn 4, Issue 10, 2003, Pages 819-828

  Mann, J John ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 5 HYDROXYINDOLEACETIC ACID; ADRENALIN; ALCOHOL; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CHOLECYSTOKININ; CHOLESTEROL; CLONIDINE; CLOZAPINE; COCAINE; DEXAMETHASONE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; HOMOVANILLIC ACID; HYDROCORTISONE; LITHIUM; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; NEUROPEPTIDE Y; NORADRENALIN; PROLACTIN; PSYCHOSTIMULANT AGENT; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE; UNINDEXED DRUG;

AGGRESSION; ALCOHOLISM; AMYGDALOID NUCLEUS; CHILD ABUSE; CIGARETTE SMOKING; CLINICAL FEATURE; DECISION MAKING; DOPAMINERGIC SYSTEM; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETICS; HEAD INJURY; HEREDITY; HUMAN; IMPULSIVENESS; MENTAL DISEASE; MODEL; NEUROANATOMY; NEUROBIOLOGY; NONHUMAN; NORADRENERGIC SYSTEM; PATIENT CARE; POSTTRAUMATIC STRESS DISORDER; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; SOCIAL PSYCHOLOGY; STRESS; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; SUICIDE;

ADOLESCENT; ANIMALS; BRAIN; BRAIN CHEMISTRY; DOPAMINE; GENE EXPRESSION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MENTAL DISORDERS; NOREPINEPHRINE; PITUITARY-ADRENAL SYSTEM; RISK FACTORS; SEROTONIN; SUICIDE;

EID: 0142153196     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn1220     Document Type: Article

References (183)

1. Beck, A. T., Weissman, A., Lester, D. & Trexler, L. Classification of suicidal behaviors. II. Dimensions of suicidal intent. Arch. Gen. Psychiatry 33, 835-837 (1976).
2. Stengel, E. Suicide and Attempted Suicide (C. Nicholls & Company Ltd., Harmondsworth, Middlesex, 1973).
3. Mann, J. J. et al. Attempted suicide characteristics and cerebrospinal fluid amine metabolites in depressed inpatients. Neuropsychopharmacology 15, 576-586 (1996).
4. Linehan, M. M. Suicidal people. One population or two? Ann. NY Acad. Sci. 487, 16-33 (1986).
5. Mann, J. J. et al. Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients. Arch. Gen. Psychiatry 49, 442-446 (1992).
6. Oquendo, M. A. et al. Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression. Arch. Gen. Psychiatry 60, 14-22 (2003).
7. Beautrais, A. L. et al. Prevalence and comorbidity of mental disorders in persons making serious suicide attempts: a case- control study. Am. J. Psychiatry 153, 1009-1014 (1996).
8. Shaffer, D. et al. Psychiatric diagnosis in child and adolescent suicide. Arch. Gen. Psychiatry 53, 339-348 (1996).
9. Robins, E., Murphy, G. E., Wilkinson, R. H. Jr, Gassner, S. & Kayes, J. Some clinical considerations in the prevention of suicide based on a study of 134 successful suicides. Am. J. Public Health 49, 888-899 (1959).
10. Murphy, G. E., Wetzel, R. D., Robins, E. & McEvoy, L. Multiple risk factors predict suicide in alcoholism. Arch. Gen. Psychiatry 49, 459-463 (1992).
11. Murphy, G. E. Suicide and substance abuse. Arch. Gen. Psychiatry 45, 593-594 (1988).
12. Henriksson, M. M. et al. Mental disorders and comorbidity in suicide. Am. J. Psychiatry 150, 935-940 (1993).
13. Frances, A., Fyer, M. & Clarkin, J. Personality and Suicide. Ann. NY Acad. Sci. 487, 281-293 (1986).
14. Jamison, K. R. Suicide and bipolar disorders. Ann. NY Acad. Sci. 487, 301-315 (1986).
15. Johns, C. A., Stanley, M. & Stanley, B. Suicide in schizophrenia. Ann. NY Acad. Sci. 487, 294-300 (1986).
16. Roy, A. & Linnoila, M. Alcoholism and suicide. Suicide Life Threat. Behav. 16, 244-273 (1986).
17. Murphy, G. E. & Wetzel, R. D. The lifetime risk of suicide in alcoholism. Arch. Gen. Psychiatry 47, 383-392 (1990).
18. Bostwick, J. M. & Pankratz, V. S. Affective disorders and suicide risk: a reexamination. Am. J. Psychiatry 157, 1925-1932 (2000).
19. Dulit, R. A., Fyer, M. R., Haas, G. L., Sullivan, T. & Frances, A. J. Substance use in borderline personality disorder. Am. J. Psychiatry 147, 1002-1007 (1990).
20. Marzuk, P. M. & Mann, J. J. Suicide and substance abuse. Psychiatr. Ann. 18, 639-645 (1988).
21. Brent, D. A. Overrepresentation of epileptics in a consecutive series of suicide attempters seen at a children’s hospital, 1978-1983. J. Am. Acad. Child Psychiatry 25, 242-246 (1986).
22. Breslau, N., Davis, G. C. & Andreski, P. Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults. Psychiatry Res. 37, 11-23 (1991).
23. Schoenfeld, M. et al. Increased rate of suicide among patients with Huntington’s disease. J. Neurol. Neurosurg. Psychiatry 47, 1283-1287 (1984).
24. Breslau, N., Kilbey, M. M. & Andreski, P. Nicotine dependence and major depression: new evidence from a prospective investigation. Arch. Gen. Psychiatry 50, 31-35 (1993).
25. Mann, J. J., Waternaux, C., Haas, G. L. & Malone, K. M. Towards a clinical model of suicidal behavior in psychiatric patients. Am. J. Psychiatry 156, 181-189 (1999).
26. Brent, D. A. et al. Personality disorder, personality traits, impulsive violence, and completed suicide in adolescents. J. Am. Acad. ChildAdolesc. Psychiatry 33, 1080-1086 (1994).
27. Cornelius, J. R. et al. Disproportionate suicidality in patients with comorbid major depression and alcoholism. Am. J. Psychiatry 152, 358-364 (1995).
28. McAllister, T. W. Neuropsychiatry sequelae of head injuries. Psychiatr. Clin. North Am. 15, 395-413 (1992).
29. Gorenstein, E. E. & Newman, J. P. Disinhibitory psychopathology: a new perspective and a model for research. Psychol. Rev. 87, 301-315 (1980).
30. Raine, A., Buchsbaum, M. & LaCasse, L. Brain abnormalities in murderers indicated by positron emission tomography. Biol. Psychiatry 42, 495-508 (1997).
31. Henriksson, M. M., Isometsa, E. T, Hietanen, P S., Aro, H. M. & Lonnqvist, J. K. Mental disorders in cancer suicides. J. Affect. Disord. 36, 11-20 (1995).
32. Marzuk, P. M. et al. Increased risk of suicide in persons with AIDS. J. Am. Med. Assoc. 259, 1333-1337 (1988).
33. Vauhkonen, K. Suicide among the male disabled with war injuries to the brain. Acta Psychiatr. Scand. 90-91 (1959).
34. Maris, R. W., Berman, A. L. & Silverman, M. M. Comprehensive Textbook of Suicidology (The Guilford Press, New York, 2000).
35. Smith, J. C., Mercy, J. A. & Conn, J. M. Marital status and the risk of suicide. Am. J. Public Health 78, 78-80 (1988).
36. Beautrais, A. L., Joyce, P. R. & Mulder, R. T. Access to firearms and the risk of suicide: a case control study. Aust. NZ J. Med. 30, 741-748 (1996).
37. Gould, M. S. Teenage suicide clusters. J. Am. Med. Assoc. 263, 2051 (1990).
38. Johnson, J. G., Cohen, P., Smailes, E. M., Kasen, S. & Brook, J. S. Television viewing and aggressive behavior during adolescence and adulthood. Science 295, 2468-2471 (2002).
39. Stanley, M., Virgilio, J. & Gershon, S. Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science 216, 1337-1339 (1982).
40. Stanley, M. & Mann, J. J. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1, 214-216 (1983).
41. 3H-paroxetine binding in cerebral cortex of suicide victims is partly due to fewer high-affinity, non-transporter sites. J. Neural Transm. 103, 1337-1350 (1996).
42. Arango, V., Underwood, M. D., Gubbi, A. V. & Mann, J. J. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res. 688, 121-133 (1995).
43. Mann, J. J. et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch. Gen. Psychiatry 57, 729-738 (2000).
44. Austin, M. C., Whitehead, R. E., Edgar, C. L., Janosky, J. E. & Lewis, D. A. Localized decrease in serotonin transporter- immunoreactive axons in the prefrontal cortex of depressed subjects committing suicide. Neuroscience 114, 807-815 (2002).
45. Ono, H. et al. Tryptophan hydroxylase immunoreactivity is altered by the genetic variation in postmortem brain samples of both suicide victims and controls. Mol. Psychiatry 7, 1127-1132 (2002).
46. Mann, J. J. & Arango, V. in Suicide: An Unnecessary Death (ed. Wasserman, D.) 29-34 (Martin Dunitz Ltd, London, 2001).
47. Areceptors in the postmortem brains of teenage suicide victims. Am. J. Psychiatry 159, 419-429 (2002).
48. Shallice, T. & Burgess, P. The domain of supervisory processes and temporal organization of behaviour. Phil. Trans. R. Soc. Lond. B 351, 1405-1412 (1996).
49. Damasio, H., Grabowski, T., Frank, R., Galaburda, A. M. & Damasio, A. R. The return of Phineas Gage: clues about the brain from the skull of a famous patient. Science 264, 1102-1105 (1994).
50. Mann, J. J. in Psychopharmacoiogy: The Fourth Generation of Progress (eds Bloom, F. E. & Kupfer, D. J.) 1919-1928 (Raven Press, New York, 1995).
51. Mann, J. J., Arango, V, Marzuk, P M., Theccanat, S. & Reis, D. J. Evidence for the 5-HT hypothesis of suicide. A review of post-mortem studies. Br. J. Psychiatry Suppl. 7-14 (1989).
52. Asberg, M., Nordstrom, P. & Traskman-Bendz, L. Cerebrospinal fluid studies in suicide. An overview. Ann. NY Acad. Sci. 487, 243-255 (1986).
53. Underwood, M. D. et al. Morphometry of the dorsal raphe nucleus serotonergic neurons in suicide victims. Biol. Psychiatry 46, 473-483 (1999).
54. Boldrini, M. et al. Increased tryptophan hydroxylase concentration in the brainstem raphe nuclei of depressed suicide victims compared to controls. American College of Neuropsychopharmacoiogy 40th Annual Meeting. 70 (2001).
55. Walther, D. J. et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299, 76 (2003).
56. Arango, V. et al. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacoiogy 25, 892-903 (2001).
57. Stockmeier, C. A. et al. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression — postmortem evidence for decrease serotonin activity. J. Neurosci. 18, 7394-7401 (1998).
58. Cooper, S. J., Kelly, C. B. & King, D. J. 5-Hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal behaviour in schizophrenia. Lancet 340, 940-941 (1992).
59. Nordstrom, P et al. CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life Threat. Behav. 24, 1-9 (1994).
60. Mann, J. J., McBride, P. A., Malone, K. M., DeMeo, M. D. & Keilp, J. G. Blunted serotonergic responsivity in depressed patients. Neuropsychopharmacoiogy 13, 53-64 (1995).
61. Coccaro, E. F. et al. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Arch. Gen. Psychiatry 46, 587-599 (1989).
62. Mann, J. J. & Malone, K. M. Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients. Bioi. Psychiatry 41, 162-171 (1997).
63. Mann, J. J., Underwood, M. D. & Arango, V. in Bioiogy of Schizophrenia and Affective Disease (ed. Watson, S. J.) 197-220 (American Psychiatric Press Inc., Washington DC, 1996).
64. Arango, V, Underwood, M. D. & Mann, J. J. Fewer pigmented locus coeruleus neurons in suicide victims: preliminary results. Bioi. Psychiatry 39, 112-120 (1996).
65. Ordway, G. A., Widdowson, P. S., Smith, K. S. & Halaris, A. Agonist binding to a2-adrenoceptors is elevated in the locus coeruleus from victims of suicide. J. Neurochem. 63, 617-624 (1994).
66. Ordway, G. A., Smith, K. S. & Haycock, J. W. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J. Neurochem. 62, 680-685 (1994).
67. Biegon, A. & Fieldust, S. Reduced tyrosine hydroxylase immunoreactivity in locus coeruleus of suicide victims. Synapse 10, 79-82 (1992).
68. Weiss, J. M. et al. Depression and anxiety: role of the locus coeruleus and corticotropin-releasing factor. Brain Res. Bull. 35, 561-572 (1994).
69. Mann, J. J., Stanley, M., McBride, P. A. & McEwen, B. S. Increased serotonin-2 and p-adrenergic receptor binding in the frontal cortices of suicide victims. Arch. Gen. Psychiatry 43, 954-959 (1986).
70. Arango, V., Ernsberger, P., Sved, A. F. & Mann, J. J. Quantitative autoradiography of a and a adrenergic receptors in the cerebral cortex of controls and suicide victims. Brain Res. 630, 271-282 (1993).
71. Weiss, G. K. et al. The effect of two different types of stress on locus coeruleus a-2 receptor binding. Brain Res. Bull. 33, 219-221 (1994).
72. Heim, C. & Nemeroff, C. B. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol. Psychiatry 49, 1023-1039 (2001).
73. Agren, H. Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid. II. Suicide. Psychiatry Res. 3, 225-236 (1980).
74. Agren, H. Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid. I. General patterns. Psychiatry Res. 3, 211-223 (1980).
75. Fawcett, J., Busch, K. A., Jacobs, D., Kravitz, H. M. & Fogg, L. Suicide: a four-pathway clinical-biochemical model. Ann. NY Acad. Sci. 836, 288-301 (1997).
76. Brown, R. P et al. Adrenocortical hyperactivity in depression: effects of agitation, delusions, melancholia, and other illness variables. Psychiatry Res. 23, 167-178 (1987).
77. Hurd, Y. L. et al. Prodynorphin mRNA expression is increased in the patch vs matrix compartment of the caudate nucleus in suicide subjects. Mol. Psychiatry 2, 495-500 (1997).
78. Ohmori, T., Arora, R. C. & Meltzer, H. Y. Serotonergic measures in suicide brain: the concentration of 5-HIAA, HVA, and tryptophan in frontal cortex of suicide victims. Biol. Psychiatry 32, 57-71 (1992).
79. 3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res. 681, 109-116 (1995).
80. Bachus, S. E., Hyde, T. M., Herman, M. M., Egan, M. F. & Kleinman, J. E. Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. J. Psychiat. Res. 31, 233-256 (1997).
81. Traskman, L., Asberg, M., Bertilsson, L. & Sjostrand, L. Monoamine metabolites in CSF and suicidal behavior. Arch. Gen. Psychiatry 38, 631-636 (1981).
82. Kapur, S. & Mann, J. J. Role of the dopaminergic system in depression. Biol. Psychiatry 32, 1-17 (1992).
83. Pitchot, W. et al. Reduced dopaminergic activity in depressed suicides. Psychoneuroendocrinology 26, 331-335 (2001).
84. Logue, A. W. et al. Cocaine decreases self-control in rats: a preliminary report. Psychopharmacology (Berl.) 109, 245-247 (1992).
85. Evenden, J. L. & Ryan, C. N. The pharmacology of impulsive behaviour in rats: the effects of drugs on response choice with varying delays of reinforcement. Psychopharmacology (Berl.) 128, 161-170 (1996).
86. Richards, J. B., Sabol, K. E. & de Wit, H. Effects of methamphetamine on the adjusting amount procedure, a model of impulsive behavior in rats. Psychopharmacology (Berl.) 146, 432-439 (1999).
87. de Wit, H., Enggasser, J. L. & Richards, J. B. Acute administration of D-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology 27, 813-825 (2002).
88. Cohen, J. D. & Servan-Schreiber, D. A theory of dopamine function and its role in cognitive deficits in schizophrenia. Schizophr. Bull. 19, 85-104 (1993).
89. Pandey, G. N. et al. Protein kinase C in the postmortem brain of teenage suicide victims. Neurosci. Lett. 228, 111-114 (1997).
90. Dwivedi, Y. et al. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch. Gen. Psychiatry 60, 273-282 (2003).
91. Dwivedi, Y. et al. mRNA and protein expression of selective a-subunits of G proteins are abnormal in prefrontal cortex of suicide victims. Neuropsychopharmacology 27, 499-517 (2002).
92. Arango, V., Underwood, M. D. & Mann, J. J. Serotonin brain circuits involved in major depression and suicide. Prog. Brain Res. 136, 443-453 (2002).
93. Dwivedi, Y. et al. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J. Neurochem. 77, 916-928 (2001).
94. Higley, J. D. et al. Paternal and maternal genetic and environmental contributions to cerebrospinal fluid monoamine metabolites in Rhesus monkeys (Macaca mulatta). Arch. Gen. Psychiatry 50, 615-623 (1993).
95. Carroll, B. J. et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch. Gen. Psychiatry 38, 15-22 (1981).
96. Bunney, W. E., Jr., Fawcett, J. A., Davis, J. M. & Gifford, S. Further evaluation of urinary 17-hydrocorticosteroids in suicidal patients. Arch. Gen. Psychiatry 21, 138-150 (1969).
97. Nemeroff, C. B., Owens, M. J., Bissette, G., Andorn, A. C. & Stanley, M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry 45, 577-579 (1988).
98. Brent, D. A. et al. Familial pathways to early-onset suicide attempt: risk for suicidal behavior in offspring of mood- disordered suicide attempters. Arch. Gen. Psychiatry 59, 801-807 (2002).
99. Viau, V., Sharma, S. & Meaney, M. J. Changes in plasma adrenocorticotropin, corticosterone, corticosteroid-binding globulin, and hippocampal glucocorticoid receptor occupancy/translocation in rat pups in response to stress. J. Neuroendocrine. 8, 1-8 (1996).
100. Hofer, M. A. On the nature and consequences of early loss. Psychosom. Med. 58, 570-581 (1996).
101. Husum, H. & Mathe, A. A. Early life stress changes concentrations of neuropeptide Y and corticotropin-releasing hormone in adult rat brain. Lithium treatment modifies these changes. Neuropsychopharmacology 27, 756-764 (2002).
102. Davidson, J. R., Hughes, D., Blazer, D. G. & George, L. K. Post-traumatic stress disorder in the community: an epidemiological study. Psychol. Med. 21, 713-721 (1991).
103. Yehuda, R., Teicher, M. H., Trestman, R. L., Levengood, R. A. & Siever, L. J. Cortisol regulation in posttraumatic stress disorder and major depression: a chronobiological analysis. Biol. Psychiatry 40, 79-88 (1996).
104. Halbreich, U. et al. Hypothalamo-pituitary-adrenal activity in endogenously depressed post-traumatic stress disorder patients. Psychoneuroendocrinology 14, 365-370 (1989).
105. Yehuda, R. et al. Low cortisol and risk for PTSD in adult offspring of holocaust survivors. Am. J. Psychiatry 157, 1252-1259 (2000).
106. Kanter, E. D. et al. Glucocorticoid feedback sensitivity and adrenocortical responsiveness in posttraumatic stress disorder. Biol. Psychiatry 50, 238-245 (2001).
107. Yehuda, R. Sensitization of the hypothalamic-pituitary- adrenal axis in posttraumatic stress disorder. Ann. NY Acad. Sci. 821, 57-75 (1997).
108. Stein, M. B., Yehuda, R., Koverola, C. & Hanna, C. Enhanced dexamethasone suppression of plasma cortisol in adult women traumatized by childhood sexual abuse. Biol. Psychiatry 42, 680-686 (1997).
109. Heim, C., Newport, D. J., Bonsall, R., Miller, A. H. & Nemeroff, C. B. Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am. J. Psychiatry 158, 575-581 (2001).
110. Westrin, A., Ekman, R. & Traskman-Bendz, L. Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt. Eur. Neuropsychopharmacol. 9, 205-211 (1999).
111. Oquendo, M. A. et al. Lower cortisol levels in depressed patients with comorbid post-traumatic stress disorder. Neuropsychopharmacology 28, 591-598 (2003).
112. Coryell, W. & Schlesser, M. The dexamethasone suppression test and suicide prediction. Am. J. Psychiatry 158, 748-753 (2001).
113. Meyer, O. C. & de Kloet, E. R. Corticosterone and serotonergic neurotransmission in the hippocampus: functional implications of central corticosteriod receptor diversity. Crit. Rev. Neurobiol. 12, 1-20 (1998).
114. Azmitia, E. C., Liao, B. & Chen, Y S. Increase of tryptophan hydroxylase enzyme protein by dexamethasone in adrenalectomized rat midbrain. J. Neurosci. 13, 5041-5055 (1993).
115. Chamas, F., Serova, L. & Sabban, E. L. Tryptophan hydroxylase mRNA levels are elevated by repeated immobilization stress in rat raphe nuclei but not in pineal gland. Neurosci. Lett. 267, 157-160 (1999).
116. Lopez, J. F., Chalmers, D. T., Little, K. Y. & Watson, S. J. A. E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry 43, 547-573 (1998).
117. Roy, A. Family history of suicide. Arch. Gen. Psychiatry 40, 971-974 (1983).
118. Roy, A., Segal, N. L., Centerwall, B. S. & Robinette, C. D. Suicide in twins. Arch. Gen. Psychiatry 48, 29-32 (1991).
119. Roy, A., Segal, N. L. & Sarchiapone, M. Attempted suicide among living co-twins of twin suicide victims. Am. J. Psychiatry 152, 1075-1076 (1995).
120. Schulsinger, F., Kety, S. S., Rosenthal, D. & Wender, P H. in Origin, Prevention and Treatment of Affective Disorders (eds Schou, M. & Stromgren, E.) 277-287 (Academic Press, New York, 1979).
121. Brent, D. A., Bridge, J., Johnson, B. A. & Connolly, J. Suicidal behavior runs in families. A controlled family study of adolescent suicide victims. Arch. Gen. Psychiatry 53, 1145-1152 (1996).
122. Statham, D. J. et al. Suicidal behaviour: an epidemiological and genetic study. Psychol. Med. 28, 839-855 (1998).
123. Manuck, S. B. et al. Aggression and anger-related traits associated with a polymorphism of the tryptophan hydroxylase gene. Biol. Psychiatry 45, 603-614 (1999).
124. Jonsson, E. G. et al. Tryptophan hydroxylase and catechol- O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur. Arch. Psychiatry Clin. Neurosci. 247, 297-302 (1997).
125. Lalovic, A. & Turecki, G. Meta-analysis of the association between tryptophan hydroxylase and suicidal behavior. Am. J. Med. Genet. 114, 533-540 (2002).
126. Lesch, K.-P et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527-1531 (1996).
127. Gorwood, P., Batel, P., Ades, J., Hamon, M. & Boni, C. Serotonin transporter gene polymorphisms, alcoholism, and suicidal behavior. Biol. Psychiatry 48, 259-264 (2000).
128. Bellivier, F. et al. Possible association between serotonin transporter gene polymorphism and violent suicidal behavior in mood disorders. Biol. Psychiatry 48, 319-322 (2000).
129. Bondy, B., Erfurth, A., de Jonge, S., Kruger, M. & Meyer, H. Possible association of the short allele of the serotonin transporter promoter gene polymorphism (5-HTTLPR) with violent suicide. Mol. Psychiatry 5, 193-195 (2000).
130. Du, L. et al. Frequency of long allele in serotonin transporter gene is increased in depressed suicide victims. Biol. Psychiatry 46, 196-201 (1999).
131. Mann, J. J., Brent, D. A. & Arango, V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology 24, 467-477 (2001).
132. Ramboz, S. et al. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc. Natl Acad. Sci. USA 95, 14476-14481 (1998).
133. 1Areceptor: glycine 22 to serine 22 and isoleucine 28 to valine 28. Biochem. Biophys. Res. Commun. 210, 530-536 (1995).
134. Huang, Y. et al. Human 5-HT1A receptor C1019G polymorphism and psychopathology. Soc. Neurosci. Abstr. 706.20 (2002).
135. Tsai, S.-J. et al. Serotonin-2A receptor polymorphism (102T/C) in mood disorders. Psychiatry Res. 87, 233-237 (1999).
136. Du, L., Bakish, D., Lapierre, Y. D., Ravindran, A. V. & Hrdina, P D. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Am. J. Med. Genet. 96, 56-60 (2000).
137. Turecki, G. et al. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am. J. Psychiatry 156, 1456-1458 (1999).
138. Geijer, T. et al. Search for association between suicide attempt and serotonergic polymorphisms. Psychiatr. Genet. 10, 19-26 (2000).
139. Zhang, H.-Y. et al. Serotoni^Areceptor gene polymorphism in mood disorders. Biol. Psychiatry 41, 768-773 (1997).
140. Ramboz, S. et al. 5-HT receptor knock out — behavioral consequences. Behav. Brain Res. 73, 305-312 (1996).
141. Rocha, B. A. et al. Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature 393, 176-178 (1998).
142. de Almeida, R. M. & Miczek, K. A. Aggression escalated by social instigation or by discontinuation of reinforcement (’frustration’) in mice: inhibition by anpirtoline: a 5-HT1B receptor agonist. Neuropsychopharmacology 27, 171-181 (2002).
143. Parsons, L. H., Weiss, F. & Koob, G. F. Serotonin 1B receptor stimulation enhances cocaine reinforcement. J. Neurosci. 18, 10078-10089 (1998).
144. 1Bgenotype and receptor binding kinetics in postmortem brain tissue. Neuropsychopharmacology 21, 238-246 (1999).
145. Lappalainen, J. et al. Linkage of antisocial alcoholism to the serotonin 5-HT1B receptor gene in 2 populations. Arch. Gen. Psychiatry 55, 989-994 (1998).
146. Huang, Y. Y. et al. Substance abuse disorder and major depression are associated with the human 5-HT1B receptor gene (HTR1B) G861C polymorphism. Neuropsychopharmacology 28, 163-169 (2003).
147. Manuck, S. B., Flory, J. D., Ferrell, R. E., Mann, J. J. & Muldoon, M. F. A regulatory polymorphism of the monoamine oxidase-A gene maybe associated with variability in aggression, impulsivity and central nervous system serotonergic responsivity. Psychiatry Res. 95, 9-23 (2000).
148. Brunner, H. G., Nelen, M., Breakefield, X. O., Ropers, H. H. & van Oost, B. A. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 262, 578-580 (1993).
149. Caspi, A. et al. Role of genotype in the cycle of violence in maltreated children. Science 297, 851-854 (2002).
150. Terwilliger, J. D. & Goring, H. H. Gene mapping in the 20th and 21st centuries: statistical methods, data analysis, and experimental design. Hum. Biol. 72, 63-132 (2000).
151. Bechara, A., Damasio, H. & Damasio, A. R. Emotion, decision making and the orbitofrontal cortex. Cereb. Cortex 10, 295-307 (2000).
152. Ingvar, D. H. The will of the brain: cerebral correlates of willful acts. J. Theor. Biol. 171, 7-12 (1994).
153. Bechara, A., Damasio, A. R., Damasio, H. & Anderson, S. W. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50, 7-15 (1994).
154. Miller, L. A. Impulsivity, risk-taking, and the ability to synthesize fragmented information after frontal lobectomy. Neuropsychologia 30, 69-79 (1992).
155. Rogers, R. D. et al. Dissociable deficits in the decision- making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology 20, 322-339 (1999).
156. Frith, C. D., Friston, K. J., Liddle, P. F. & Frackowiak, R. S. J. Willed action and the prefrontal cortex in man: a study with PET. Proc. R. Soc. Lond. B 244, 241-246 (1991).
157. Davidson, R. J., Putnam, K. M. & Larson, C. L. Dysfunction in the neural circuitry of emotion regulation — a possible prelude to violence. Science 289, 591-594 (2000).
158. Blair, R. J., Morris, J. S., Frith, C. D., Perrett, D. I. & Dolan, R. J. Dissociable neural responses to facial expressions of sadness and anger. Brain 122, 883-893 (1999).
159. Morgan, M. A., Romanski, L. M. & LeDoux, J. E. Extinction of emotional learning: contribution of medial prefrontal cortex. Neurosci. Lett. 163, 109-113 (1993).
160. Gewirtz, J. C. & Falls, W. A. Normal conditioned inhibition and extinction of freezing and fear-potentiated startle following electrolytic lesions of medical prefrontal cortex in rats. Behav. Neurosci. 111, 712-726 (1997).
161. Drevets, W. C. et al. A functional anatomical study of unipolar depression. J. Neurosci. 12, 3628-3641 (1992).
162. Mann, J. J. et al. Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am. J. Psychiatry 153, 174-182 (1996).
163. 18F]fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology 20, 413-423 (1999).
164. Raine, A. et al. Reduced prefrontal and increased subcortical brain functioning assessed using positron emission tomography in predatory and affective murderers. Behav. Sci. Law 16, 319-332 (1998).
165. Hoptman, M. J. et al. Frontal white matter microstructure, aggression, and impulsivity in men with schizophrenia: a preliminary study. Biol. Psychiatry 52, 9-14 (2002).
166. Mann, J. J. Neurobiology of Suicide and Aggression. ACNP Fourth Generation of Progress, (2000).
167. Dalley, J. W., Theobald, D. E., Pereira, E. A., Li, P. M. & Robbins, T. W. Specific abnormalities in serotonin release in the prefrontal cortex of isolation-reared rats measured during behavioural performance of a task assessing visuospatial attention and impulsivity. Psychopharmacology (Berl.) 164, 329-340 (2002).
168. Heidbreder, C. A. et al. Behavioral, neurochemical and endocrinological characterization of the early social isolation syndrome. Neuroscience 100, 749-768 (2000).
169. Sahakian, B. J., Robbins, T. W., Morgan, M. J. & Iversen, S. D. The effects of psychomotor stimulants on stereotypy and locomotor activity in socially-deprived and control rats. Brain Res. 84, 195-205 (1975).
170. Dias, R., Robbins, T. W. & Roberts, A. C. Dissociation in prefrontal cortex of affective and attentional shifts. Nature 380, 69-72 (1996).
171. Jaskiw, G. E. et al. Effect of ibotenic acid lesions of the medial prefrontal cortex on amphetamine-induced locomotion and regional brain catecholamine concentrations in the rat. Brain Res. 534, 263-272 (1990).
172. Womack, S. et al. Medial frontal cortex lesions: deficits and treatment with nimodipine. Exp. Neurol. 124, 387-389 (1993).
173. Hirschfeld, R. M. & Russell, J. M. Assessment and treatment of suicidal patients. N. Engl. J. Med. 337, 910-915 (1997).
174. Baldessarini, R. J., Tondo, L. & Hennen, J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J. Clin. Psychiatry 60, 77-84 (1999).
175. Nilsson, A. Lithium therapy and suicide risk. J. Clin. Psychiatry 60, 85-88 (1999).
176. Meltzer, H. Y. & Okayli, G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry 152, 183-190 (1995).
177. Walker, A. M., Lanza, L. L., Arellano, F. & Rothman, K. J. Mortality in current and former users of clozapine. Epidemiology 8, 671-677 (1997).
178. Reid, W. H., Mason, M. & Hogan, T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatric Services 49, 1029-1033 (1998).
179. Oquendo, M. A. et al. Postmortem frontal cortex 5HT2A binding is higher in suicide victims with elevated lifetime aggression. American College of Neuropsycopharmacology 39th Annual Meeting, 85 (2000).
180. Muldoon, M. F., Manuck, S. B. & Matthews, K. A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Br. Med. J. 301, 309-314 (1990).
181. Muldoon, M. F. et al. Low or lowered cholesterol and risk of death from suicide and trauma. Metabolism 42, 45-56 (1993).
182. Golomb, B. A. Cholesterol and violence: is there a connection? Ann. Intern. Med. 128, 478-487 (1998).
183. Kaplan, J. R. et al. Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behavior in monkeys. Psychosom. Med. 56, 479-484 (1999).